3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
177
Neoplasm Metastasis
19
Breast Neoplasms
19
Prostatic Neoplasms, Castration-Resistant
17
Neoplasms
17
Metastatic Castration Resistant Prostate Cancer
8
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Triple Negative Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Castration-resistant Prostate Cancer
4
Carcinoma, Hepatocellular
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Prostate Adenocarcinoma
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
mCRPC
2
Uterine Cervical Neoplasms
2
Recurrence
2
Prostatic Diseases
2
Metastatic Hormone Sensitive Prostate Cancer
2
Interventions
Fluorouracil
26
Radiotherapy
17
Mitomycin
17
Cisplatin
12
Capecitabine
12
pembrolizumab
10
Cyclophosphamide
9
Radiation
8
Paclitaxel
8
fludarabine
7
Specimen Handling
7
Nivolumab
7
Carboplatin
7
Magnetic Resonance Spectroscopy
6
Cetuximab
6
Biopsy
6
Papillomavirus Vaccines
5
Drug Therapy
5
dehydroftorafur
4
aldesleukin
4
Vaccines
4
Radiotherapy, Intensity-Modulated
4
Irinotecan
4
Watchful Waiting
3
Taxes
3
Oxaliplatin
3
Observation
3
Light Coagulation
3
Ipilimumab
3
Interleukin-2
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Anus Neoplasms
×
enzalutamide
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts